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Efﬁcacy and safety of vildagliptin and voglibose in Japanese
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Aim: To conﬁrm the efﬁcacy of vildagliptin in patients with type 2 diabetes (T2D) by testing the hypothesis that glycosylated haemoglobin
(HbA1c) reduction with vildagliptin is superior to that with voglibose after 12 weeks of treatment.
Methods: In this 12-week, randomized, double-blind, active-controlled, parallel-group study, the efﬁcacy and safety of vildagliptin (50 mg bid,
n = 188) was compared with that of voglibose (0.2 mg tid, n = 192) in patients with T2D who were inadequately controlled with diet and
exercise.
Results: The characteristics of two groups were well matched at baseline. The mean age, body mass index (BMI) and HbA1c were 59.1 years,
24.9 kg/m2 and 7.6%, respectively. At baseline, fasting plasma glucose (FPG) and 2-h postprandial glucose (PPG) were 9.01 mmol/l
(162.2 mg/dl) and 13.57 mmol/l (244.3 mg/dl), respectively. The adjusted mean change in HbA1c from baseline to endpoint was
−0.95 ± 0.04% in the vildagliptin-treated patients and −0.38 ± 0.04% in those receiving voglibose (between-group change = 0.57 ± 0.06%,
95% conﬁdence interval (CI) (−0.68 to −0.46%), p < 0.001), showing that vildagliptin was superior to voglibose. Endpoint HbA1c ≤ 6.5%
was achieved in 51% vildagliptin-treated patients compared with 24% patients who were on voglibose (p < 0.001). Vildagliptin also exhibited
signiﬁcantly (p < 0.001) greater reduction compared with voglibose in both FPG [1.34 vs. 0.43 mmol/l (24.1 vs. 7.8 mg/dl)] and 2-h PPG
[2.86 vs. 1.1 mmol/l (51.5 vs. 19.8 mg/dl)]. Overall adverse events (AEs) were lower in the vildagliptin-treated patients compared with
that in the voglibose-treated patients (61.2 vs. 71.4%), with no incidence of hypoglycaemia and serious adverse events with vildagliptin.
Gastrointestinal AEs were signiﬁcantly lower with vildagliptin compared with that of the voglibose (18.6 vs. 32.8%; p = 0.002).
Conclusions: Vildagliptin (50 mg bid) showed superior efﬁcacy and better tolerability compared with voglibose in Japanese patients with T2D.
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Introduction
T h ep r e v a l e n c eo ft y p e2d i a b e t e s( T 2 D )i si n c r e a s i n gw o r l d -
wide, and an estimated ∼8.9 million diabetic cases are being
reported in Japan [1,2]. Despite major advancement in the
treatment for T2D, optimal glycaemic control remains elu-
sive [3]. The undesirable effects associated with many of
the available treatment options complicate the treatment
of T2D [4,5]. Therefore, novel therapeutic strategies capable
of delivering better antihyperglycaemic efﬁcacy with a low
frequency of undesirable effects are required.
Voglibose, an α-glucosidase inhibitor, is one of the most
commonly used oral antidiabetic drug (OAD) in Japan.
α-Glucosidase inhibitor is prescribed not only as a ﬁrst-
line treatment but also as an add-on to other OADs and
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insulin [6]. The postprandial glucose (PPG) control exercised
by α-glucosidase inhibitor is of utmost importance, because
this is known to reduce cardiovascular events [7,8]. Voglibose
decreases the level of PPG with very low risk of hypogly-
caemia, but is associated with frequent gastrointestinal (GI)
side effects [9].
The development of dipeptidyl peptidase-IV (DPP-4)
inhibitors, such as vildagliptin, has led to the improvement
in glycaemic control in T2D by preventing the degradation
of the incretin hormones glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic polypeptide. In addi-
tion, vildagliptin treatment improves pancreatic β-cell and
α-cell function [10,11], leading to reduced PPG levels. Sev-
eral clinical trials have showed the efﬁcacy of vildagliptin in
patients with T2D either as monotherapy or in combination
withmetformin [12],thiazolidinedione [13],sulfonylurea [14]
or insulin [15] without clinically signiﬁcant weight gain and
with minimal hypoglycaemia. In a 12-week study in Japanese
patients with T2D, treatment with vildagliptin was shown toDIABETES, OBESITY AND METABOLISM original article
exert dose-dependent glycaemic control and was well toler-
ated [16]. As treatment with vildagliptin has showed beneﬁts
beyond glycaemic control such as lowering of pancreatic
α-cell glucagon levels [10,17] and preservation of pancreatic
β-cell function [18,19], vildagliptin may be a better therapeu-
tic option compared with voglibose.
This study aimed to conﬁrm the efﬁcacy of vildagliptin in
patientswithT2Dbytestingthehypothesisthattheglycosylated
haemoglobin (HbA1c) reduction with vildagliptin is superior
to that with voglibose after 12 weeks of treatment.
Methods
Study Design
This randomized, double-blind, active-controlled, parallel-
group study was conducted at 51 centres in Japan. Subsequent
toa2-weekrun-inperiod,alleligiblepatientswererandomized
(1 : 1) to receive either vildagliptin 50 mg bid or voglibose
0.2 mg tid for 12 weeks.
Study Population
T 2 Dp a t i e n t s[ a g e d≥20 years, body mass index (BMI)
20–35 kg/m2] with HbA1c of 6.5–10%, fasting plasma glu-
cose (FPG) of<15 mmol/l (270 mg/dl) and those who had not
taken OAD for at least 8 weeks before the study entry were
enrolled. Patients who received diet/exercise therapy for at
least8 weeks and agreed to maintainit during the course ofthe
studywerealsoeligible.Femalepatients withnon-childbearing
potential or those using a medically approved birth control
method were included.
Any history of type 1 or secondary forms of diabetes, acute
metabolic diabetic complications 6 months before the study,
congestive heart failure requiring pharmacological treatment,
myocardial infarction, unstable angina, or coronary artery
bypass surgery within 1 year, led to exclusion from the study.
Patients with renal disease or dysfunction (i.e. elevated serum
creatinine levels) and liver disease such as cirrhosis or chronic
active hepatitis were also excluded from the study. Concomi-
tant medications with any OADs, chronic corticosteroids (oral
orparenteral,>7consecutivedaysoftreatment)andclassesIa,
Ib, Ic or III antiarrhythmic medications were not permitted.
Study Assessments
The variables HbA1c (measured by HPLC), FPG, fasting
insulin, C-peptide and body weight were all measured at
screening and at weeks 0, 2, 4, 8 and 12; whereas fasting lipid
proﬁlewasmeasuredatscreening,weeks 0and12.Homeostasis
model assessment (HOMA)-β and HOMA-R were calculated
as a function of FPG and insulin, respectively. The standard
meal challenge assessment was performed at weeks 0 and 12.
For the meal challenge, patients were fasted overnight, and the
study drug was administered 5 min before starting a standard
400 kcal breakfast meal (protein, 14.4 g; carbohydrate, 60.5 g;
lipids, 9.4 g). Blood samples for the determination of glucose
andinsulinwere obtainedat20and 0 minbeforeandat60and
120 min after the start of the meal.
All the adverse events (AEs) were recorded and assessed
for severity and possible relationship to study medication.
Patients were provided with and instructed on the use of a
self-monitored blood glucose (SMBG) device. Hypoglycaemia
was deﬁned as symptoms suggestive of low blood glucose and
further conﬁrmed using SMBG measurement <3.1 mmol/l
(56 mg/dl) plasma glucose equivalent. Severe hypoglycaemia
was deﬁned as any episode; wherein, the patient was unable to
initiate self-treatment and required the assistance of another
person or hospitalization.
Physical examinations, vital signs, 12-lead ECG and labo-
ratory assessments comprising routine haematology, routine
biochemistry and urinalysis were monitored. All laboratory
assessments were made by the central laboratory (Mitsubishi
Kagaku Bio-Clinical Laboratories, Tokyo, Japan).
Data Analysis
A sample size of 370 randomized patients (185 per group)
was targeted assuming a 10% drop-out rate and a standard
deviation of 1. This would provide a 95% power to detect a
statisticallysuperior difference of0.4% from baseline in reduc-
ing HbA1c between the two treatment groups using two-sided
signiﬁcance level of 0.05.
The efﬁcacyanalyses were performed with datafromthe full
analysis set (FAS) population deﬁned as all the randomized
patientswhoreceivedatleastonedoseofstudydrugandhadat
least one postbaseline assessment. The last observation carried
forward (LOCF) method was used for patients who discontin-
uedearly.Theprimaryefﬁcacyvariable,changeinHbA1cfrom
baseline at the study endpoint, was analysed for superiority of
vildagliptin 50 mg bid over voglibose 0.2 mg tid. Changes in
FPG, fastingplasma lipids and body weight were the secondary
efﬁcacy parameters.
Several criteria were prespeciﬁed to classify patients as
responders to treatment: percentage of patients (i) achieving
HbA1c≤ 6.5%,(ii)experiencinga≥1.0%reductioninHbA1c,
(iii)experiencinga≥0.7%reductioninHbA1c,(iv)experienc-
ing a ≥0.5% reduction in HbA1c and (v) meeting at least one
of the aforementioned criteria in both treatment groups.
Thechangesfrombaselineinefﬁcacyvariableswereanalysed
using an ANCOVA model, with treatment and pooled centre as
the classiﬁcation factor and baseline as the covariate. The
between-treatment differences and the related two-sided 95%
conﬁdence interval (CI) for the adjusted mean change for the
primaryandthesecondaryefﬁcacyvariableswerealsoanalysed.
Prespeciﬁed subanalyses of HbA1c were conducted based on
initial (baseline) HbA1c.
Safety assessment was performed on safety (SAF) popula-
tion and consisted of all subjects who received at least one
dose of the study drug and had at least one postbaseline safety
assessment.SafetyassessmentsfortheincidenceofGIAEswere
summarized by preferred term for each treatment group, and
the overallincidence ofGIAEs between bothtreatment groups
was compared using a Fisher’s exact test.
Ethics and Good Clinical Practice
All participants provided written informed consent. The
protocol was approved by the independent ethics committee/
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institutional review board at each study site, and the study was
conductedusing GoodClinicalPracticein accordancewiththe
Declaration of Helsinki.
Results
Patient Disposition and Baseline Characteristics
All randomized patients took the study drug (vildagliptin,
n = 188; voglibose, n = 192). A comparable proportion of
patients completed the study in both treatment groups
[vildagliptin: 95.2% (n = 179), voglibose: 94.8% (n = 182)].
Figure 1 summarizes the patient disposition. The number
of discontinuations and reasons for discontinuation in both
treatmentarmsweresimilar.Patientcompliancewiththestudy
medicationwas97.9and99.0%inthevildagliptinandvoglibose
groups, respectively.
Thedemographicandbaselinecharacteristicsoftherandom-
ized patients are summarized in Table 1. The groups were well
balanced for all the baseline characteristics: mean BMI, 24.9 ±
3.2k g / m 2;H b A 1 c ,7 .6 ± 0.9 % ;F P G ,9 .01 ± 1.77 mmol/l
(162.2 ± 31.9 mg/dl); 2-h PPG,13.57 ± 2.98 mmol/l(244.3 ±
53.6 mg/dl). The mean values of age and duration of diabetes
were 59.1 ± 10 and 5.4 ± 5.1 years, respectively.
Efﬁcacy Results
Figure 2 shows reduction in the HbA1c levels. Greater reduc-
tion as early as week 2 was evident with the vildagliptin 50 mg
bid group compared with the voglibose 0.2 mg tid group
(Figure 2A). At the week 12 endpoint, the adjusted mean
of HbA1c reduction from baseline was 0.95 and 0.38% in
the vildagliptin and voglibose treatment groups, respectively.
The between-treatment difference (vildagliptin–voglibose) in
adjusted mean change in HbA1c reduction was signiﬁcant
[0.57 ± 0.06%, 95% CI (−0.68 to −0.46%), p < 0.001],
demonstrating that vildagliptin 50 mg bid was superior to
voglibose 0.2 mg tid (Figure 2B).
The reduction in HbA1c from baseline was the highest in
the >8% category among the subgroups stratiﬁed according
tobaseline HbA1c(vildagliptin: 1.35%;voglibose:0.49%). The
changesinHbA1cweresimilarinalltheothersubgroups(base-
line BMI, age, gender and glomerular ﬁltration rate) (Table 2).
Responder Rates
The percentage of responders (target HbA1c ≤ 6.5% at
endpoint) was signiﬁcantly higher with vildagliptin 50 mg bid
compared with that to voglibose 0.2 mg tid (50.8 vs. 24.2%,
Figure 1. Patients’ disposition.
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Table 1. Baseline characteristics of the randomized population.
Demographic variable Vildagliptin 50 mg bid N = 188 Voglibose 0.2 mg tid N = 192
Age (years)∗ 60.3 (±10.48) 58.0 (±9.32)
Age category ≥65 years† 68 (36.2%) 52 (27.1%)
Gender†
Male 121 (64.4%) 130 (67.7%)
Female 67 (35.6%) 62 (32.3%)
Body weight∗ 64.4 (±10.8) 66.5 (±10.3)
BMI (kg/m2)∗ 24.8 (±3.05) 25.0 (±3.35)
HbA1c (%)∗ 7.5 (±0.9) 7.6 (±0.9)
FPG (mmol/l)∗ 8.9 (±1.7) [160.4 (±30.1)]$ 9.1 (±1.9) [164 (±33.5)]$
1-h PPG (mmol/l)∗ 15.2 (±2.2) [272.8 (±40.1)]$ 15.0 (±2.4) [270 (±43.3)]$
2-h PPG (mmol/l)∗,‡ 13.6 (±3.0) [244.9 (±53.2)]$ 13.5 (±3.0) [243.8 (±54.2)]$
Duration of T2D (years)∗ 5.1 (±5.1) 5.6 (±5.0)
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; PPG, postprandial glucose; T2D, type 2 diabetes.
∗Mean (±s.d.).
†n( % ) .
‡N = 187 for vildagliptin 50 mg bid group.
$mg/dl.
Figure 2. Panel (A): changes in mean (±s.e.) HbA1c during the 12-
week treatment with vildagliptin 50 mg bid (open triangles) or voglibose
0.2 mg tid (closed circles). Panel (B): least square mean (±s.e.) change in
HbA1c at endpoint under treatment with vildagliptin 50 mg bid (white
bar) or voglibose 0.2 mg tid (black bar). *p < 0.001 vs voglibose. HbA1c,
haemoglobin A1c.
p < 0.001). A higher proportion of patients in the vildagliptin
group met the responder criteria of ≥1% reduction in HbA1c
(43.1 vs. 15.1%), ≥0.7% reduction in HbA1c (66.5 vs. 31.3%),
and a ≥0.5% reduction in HbA1c (83 vs. 44.8%) compared
with patients in the voglibose groups. The treatment response
in terms of reduction of HbA1c meeting in at least one of
the aforementioned criteria was 84% in the vildagliptin group
and 51.6% in the voglibose group. In all other deﬁnitions,
the percentage of responders was signiﬁcantly higher in the
vildagliptin group compared with that of the voglibose group
(p < 0.001 in all criteria, Chi-squared test).
Fasting Plasma Glucose
Figure 3 shows reduction in FPG levels. In the vildagliptin
group, the onset of reduction was observed as early as
week 2 and continued until week 12 (Figure 3A). At end-
point (week 12), the adjusted mean change in FPG reduction
from baseline was greater in patients receiving vildagliptin
[−1.34 ± 0.09 mmol/l (−24.1 ± 1.54 mg/dl)] compared with
those receiving voglibose [−0.43 ± 0.08 mmol/l (−7.8 ±
1.52 mg/dl)] (Figure 3B), with between-treatment difference
[0.91 ± 0.12 mmol/l(16.3 ± 2.1 mg/dl)]beingstatisticallysig-
niﬁcant (p < 0.001).
Fasting Insulin and C-Peptide
The fasting insulin at baseline was 7.96 ± 0.4a n d8 .2 ±
0.4 mU/l in the vildagliptin and voglibose groups, respectively.
The absolute change from baseline in fasting insulin was lower
in the vildagliptin group (−0.22 mU/l) compared with that of
the voglibose group (−0.67 mU/l); and the difference between
the groups was not signiﬁcant (p = 0.154).
The baseline C-peptide levels (2.4 ± 0.1μg/l) and reduction
from baseline (∼0.1 μg/l) were similar in the vildagliptin and
voglibose groups.
Meal Test
Postprandial Plasma Glucose. Figure 4A shows the change
in PPG at baseline and at the endpoint. At baseline, the
changes in PPG were similar in both groups (Table 1). After
12 weeks of treatment, the change in 1-h [−2.94 ± 0.12 vs.
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Table 2. Change in HbA1c from baseline at endpoint in subgroups (FAS).
Vildagliptin 50 mg bid (N = 188) Voglibose 0.2 mg tid (N = 192)
Subgroup category n∗ Baseline mean Change from baseline mean (s.e.) n∗ Baseline mean Change from baseline mean (s.e.)
Baseline HbA1c (%)
≤76 5 6 . 7 3 −0.56 (0.043) 65 6.71 −0.27 (0.060)
>7, ≤87 1 7 . 4 2 −0.95 (0.049) 72 7.49 −0.37 (0.064)
>85 2 8 . 7 3 −1.35 (0.094) 55 8.85 −0.49 (0.112)
BMI at baseline
<25 kg/m2 107 7.49 −0.96 (0.056) 106 7.59 −0.37 (0.049)
≥25kg/m2 81 7.62 −0.88 (0.063) 86 7.65 −0.38 (0.081)
Age (years)
<65 120 7.67 −0.93 (0.054) 140 7.67 −0.36 (0.054)
≥65 68 7.31 −0.91 (0.066) 52 7.46 −0.42 (0.080)
Gender
Male 121 7.55 −0.98 (0.051) 130 7.67 −0.41 (0.060)
Female 67 7.53 −0.81 (0.072) 62 7.51 −0.30 (0.062)
FPG at baseline (mmol/l)
<8.9 (160 mg/dl) 103 7.10 −0.82 (0.052) 98 7.11 −0.44 (0.046)
≥8.98 5 8 . 0 8 −1.05 (0.066) 94 8.14 −0.31 (0.078)
GFR MDRD at baseline [(ml/min)/(1.73 m2)]
Normal >80 170 7.57 −0.92 (0.045) 179 7.61 −0.36 (0.047)
Mild >50 to ≤80 18 7.27 −0.92 (0.090) 13 7.67 −0.48 (0.174)
2-h PPG level at baseline (mmol/l)
<12.2 (220 mg/dl) 64 6.94 −0.75 (0.055) 61 7.04 −0.40 (0.060)
≥12.2 123 7.86 −1.02 (0.055) 131 7.88 −0.36 (0.060)
No data 1 6.60 0.00
BMI, body mass index; FPG, fasting plasma glucose; GFR, glomerular ﬁltration rate; MDRD, modiﬁcation of diet in renal disease; PPG, postprandial
glucose.
∗n is the number of subjects with observations at both baseline and endpoint.
−2.64 ± 0.12 mmol/l (−52.9 ± 2.2v s . −47.6 ± 2.2m g / d l ) ]
and 2-h [−2.86 ± 0.13 vs. −1.1 ± 0.13 mmol/l (51.5 ± 2.4v s .
−19.8 ± 2.4 mg/dl)]. PPG from baseline was greater in the
vildagliptin group compared with that of the voglibose group.
The difference between the groups was signiﬁcant (p < 0.001)
only for the change in 2-h PPG from baseline (Figure 4A, B).
Postprandial Insulin. At baseline, 1-h postprandial insulin was
34.5 ± 1.8and31.4 ± 1.4mU/l,respectively,and2-hpostpran-
dial insulin was 31.8 ± 1.7a n d2 9 .7 ± 1.5 mU/l, respectively,
for vildagliptin and voglibose treatment groups. The 1-h and
2-h postprandial insulin decreased from baseline in both treat-
mentgroups(vildagliptinvs.voglibose:−3.7 ± 0.9v s .−12.9 ±
0.9;−2.4 ± 1.0v s .−7.1 ± 1.0; respectively), with difference
between them being statistically signiﬁcant (p < 0.001).
HOMA-β and HOMA-R
BaselineHOMA-β andHOMA-Rweresimilarinthetreatment
groups (vildagliptin, 31.6 ± 1.6a n d3 .2 ± 0.2; voglibose,
31.8 ± 1.6a n d3 .3 ± 0.2). At endpoint, the adjusted mean
change in HOMA-β from baseline was greater in vildagliptin
(8.2 ± 1.1) compared with that of the voglibose (0.4 ± 1.1)
and the difference between them (7.8 ± 1.5) was statistically
signiﬁcant (p < 0.001). HOMA-β at endpoint in vildagliptin
was 39.7 ± 2.0%. HOMA-R decreased in both groups from
baseline at endpoint (vildagliptin, −0.5 ± 0.1; voglibose,
−0.40); however, the difference between the groups was not
statistically signiﬁcant (p = 0.367).
Fasting Lipid and Body Weight
In the FAS population, the baseline triglyceride, total choles-
terol, low-density lipoprotein (LDL), high-density lipoprotein
(HDL), non-HDL and very low-density lipoprotein (VLDL)
in the vildagliptin group were 148.1 ± 6.7, 205.9 ± 2.1,
128.7 ± 2.1, 54.8 ± 1.1, 151.1 ± 2.2, 29.6 ± 1.4m g / d l a n d
0.6 mequiv./l, respectively and in the voglibose group the
levels were 139.5 ± 7.0, 206.9 ± 2.5, 131.2 ± 2.3, 53.7 ± 1,
153.2 ± 2.5, 27.9 ± 1.4 mg/dl and 0.7 mequiv./l, respectively.
The total cholesterol, LDL and non-HDL decreased in the
vildagliptin group (−3.1 ± 0.9, −1.9 ± 1.3, −3.2 ± 1.1%),
whereas it increased in the voglibose group (4.5 ± 0.9,
9.3 ± 1.3, 6.8 ± 1.1%) and the difference between the treat-
ment groups was signiﬁcant (p < 0.001 for each). The HDL
level decreased with both vildagliptin and voglibose treat-
ment (−1.5 and −0.8%, respectively); however, the difference
between them was not statistically signiﬁcant (p = 0.613).
In the vildagliptin group, the body weight increased by
0.2 kg, whereas in the voglibose group a decrease of 0.8 kg
was noted. The difference between the groups was statistically
signiﬁcant (p < 0.001).
Tolerability
TheoverallincidenceofanyAEs,seriousadverseevents(SAEs)
or suspected drug-related AEs was lower in the vildagliptin
group compared with that of the voglibose group (Table 3).
The incidence of suspected drug-related AEs was lower with
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Figure 3. Panel(A):changeinmean(±s.e.)fastingplasma glucose(FPG)
during the 12-week treatment with vildagliptin 50 mg bid (open triangles)
orvoglibose0.2 mgtid(closedcircles).Panel(B):leastsquaremean(±s.e.)
change in FPG at endpoint under treatment with vildagliptin 50 mg bid
(white bar) or voglibose (black bar). 140 and 160 mg/dl are equivalent to
7.8 and 8.9 mmol/l, respectively. *p < 0.001 vs voglibose.
vildagliptin compared with that of the voglibose (25.0 vs.
40.6%). The most common suspected drug-related AEs by
systemorganclasswas‘gastrointestinaldisorders’(vildagliptin:
11.7%, voglibose: 24.0%). GI AEs were signiﬁcantly lower in
patients treated with vildagliptin (18.6%) compared with that
in those treated with voglibose (32.8%) (p = 0.002 Fisher’s
exact test) (Table 3). Nasopharyngitis was the most common
AE in both treatment groups but was not suspected to be as a
result of the drugs studied.
No hypoglycaemic events were observed in the vildagliptin
group, whereas one patient in the voglibose group experienced
a mild hypoglycaemic event. No incidence of hepatic enzymes
abnormalities (≥3 times the upper limit of normal range) for
aspartate aminotransferase (AST), alanine aminotransferase
(ALT) and alkaline phosphatase (ALP) was noted in any of the
groups.
No deaths were reported in this study. There were no SAEs
in the vildagliptin group; however, in the voglibose group
four patients reported ﬁve SAEs (colonic polyp, hand fracture,
rib fracture, syncope and asthma) that were not study drug
Figure 4. Panel (A): least square mean (±s.e.) change in 1 h postprandial
plasmaglucose(PPG)atendpointundertreatmentwithvildagliptin 50 mg
bid (white bar) or voglibose (black bar). Panel (B): least square mean
(±s.e.) change in 2 h PPG at endpoint under treatment with vildagliptin
50 mg bid (white bar) or voglibose (black bar). Twenty and 40 mg/dl are
equivalent to 1.1 and 2.2 mmol/l, respectively. *p < 0.001 vs voglibose.
related. Changes from baseline for the haematology, blood
biochemistry and urinalysis measurements at endpoint were
not clinically signiﬁcant.
Discussion
In this 12-week study, vildagliptin 50 mg bid was superior
in reducing HbA1c levels compared with voglibose 0.2 mg
tid (−0.95 vs. −0.38%; p < 0.001). Greater reduction in the
HbA1c levels was evident in all subgroups, including age,
genderandBMI,inpatientstreatedwithvildagliptincompared
with that in the voglibose-treated patient group. Vildagliptin
also showed a signiﬁcant reduction in FPG and 2-h PPG from
baselinecomparedwithvoglibose(p < 0.001).Vildagliptinwas
welltoleratedwithnoeventsofhypoglycaemiaandsigniﬁcantly
less GI AEs.
The HbA1c reduction observed in this study (0.95%) with
vildagliptin 50 mg bid was comparable with the previously
reported reduction of 0.92% in Japanese patients with
vildagliptin 50 mg bid [16]. As the baseline levels of HbA1c
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Table 3. Incidence of AEs, SAEs and hypoglycaemic events in treatment
groups (safety population).
Patient
Vildagliptin 50 mg
bid (N = 188) n (%)
Voglibose 0.2 mg
tid (N = 192) n (%)
All AEs∗ 115 (61.2) 137 (71.4)
Speciﬁc AEs (occurring in >4% of any group)
Nasopharyngitis 34 (18.1) 32 (16.7)
Constipation 13 (6.9) 13 (6.8)
Flatulence 6 (3.2) 23 (12.0)
Abdominal distension 4 (2.1) 14 (7.3)
Diarrhoea 3 (1.6) 11 (5.7)
Alanine aminotransferase
increased
3 (1.6) 11 (5.7)
Suspected drug-related AE† 47 (25.0) 78 (40.6)
Hypoglycaemia 0 (0.0) 1 (0.5)
SAEs 0 (0.0) 4 (2.1)
Discontinuations as a result
of AE
4 (2.1) 4 (2.1)
Any GI event (detail below) 35 (18.6)‡ 63 (32.8)
Constipation 13 (6.9) 13 (6.8)
Flatulence 6 (3.2) 23 (12.0)
Dyspepsia 5 (2.7) 0 (0.0)
Abdominal distension 4 (2.1) 14 (7.3)
Abdominal pain upper 3 (1.6) 3 (1.6)
Diarrhoea 3 (1.6) 11 (5.7)
Stomach discomfort 2 (1.1) 1 (0.5)
Deaths 0 (0.0) 0 (0.0)
AE, adverse event; GI, gastro intestinal; SAE, serious adverse events.
∗A subject with multiple occurrences of an adverse event was counted
onlyonce in the adverseevent category. When a subject exhibited multiple
occurrences of an adverse event in categories of different severity, the
subject was counted in the category of worst severity.
†Adverse events occurring in 4% of each group.
‡p-Value 0.002.
increased from ≤7t o>8, a greater reduction in HbA1c was
seen in the vildagliptin 50 mg bid group (-0.56 to −1.35%)
compared with that of the voglibose 0.2 mg tid group (−0.27
to −0.49%). Thus in this study, the efﬁcacy of vildagliptin has
been showed across a wide range of severity of T2D as deﬁned
by HbA1c levels. A higher proportion of patients had HbA1c
levels≤6.5%withvildagliptincomparedwiththatofvoglibose
(51 vs. 24%; p < 0.001).
The overall efﬁcacy of reduction in HbA1c is essentially
the sum of effects on FPG and PPG. In this study, signif-
icantly greater FPG reduction from baseline was observed
withvildagliptin versus voglibose [1.34 vs. 0.4 mmol/l(24.1 vs.
7.8 mg/dl); p < 0.001]. The reduction in 1-h PPG was simi-
lar and that in 2h-PPG levels was signiﬁcantly greater in the
vildagliptin group compared with that in the voglibose group
(Figure 4B, p < 0.001). α-Glucosidaseinhibitors are known to
exert glycaemic control by reducing PPG [20,21]; however, in
thisstudyvildagliptinshowedbetterPPGreducingabilitycom-
pared with voglibose. Thus, the overall superior reduction in
HbA1cseeninthevildagliptingroupcomparedwiththatin the
voglibose group is essentially because of better reductions in
boththe FPGandthePPGlevels.These ﬁndingssatisfythepri-
marygoalofdiabetesmanagementassetbytheIDFguidelines,
which is normalization of the glycaemic status with HbA1c,
FPG and PPG as markers of disease control [22]. Thus, this
study reveals that 24-h plasma glucose control, an important
aspect of glycaemic control, would be better in the vildagliptin
group compared with that in the voglibose group. A growing
body of evidence suggests postmeal hyperglycaemia to be an
independent riskfactorforthedevelopmentofmacro-vascular
disease [23]. Oxidative stress, subclinical inﬂammation of the
vasculature and abnormal carotid intima-medial thickness as
an outcome of PPG spikes lead to cardiovascular disease [24].
Thus,treatmenttotargetpostmealhyperglycaemiaisimportant
to reduce the risk of both micro- and macro-vascular compli-
cations in patients with T2D. Early intensiﬁcation of treatment
could decrease the risk of progression of micro-vascular
complications and the damage of β-cell caused by chronic
hyperglycaemia [22,23]. Controlling postmeal hyperglycaemia
with acarbose, an α-glucosidase inhibitor, is associated with a
signiﬁcant reduction in the incidence of cardiovascular disease
and hypertension [25]. As treatment with vildagliptin 50 mg
bid showed greater efﬁcacy in controlling PPG, HbA1c and
FPG compared with voglibose, it could be a more appealing
alternative for better glycaemic control.
In thisstudy,bothtreatmentsresulted indecrease postpran-
dialinsulinlevelswiththeextentbeinglesserinthevildagliptin
groupcomparedwiththatinthevoglibosegroup.Insulinsecre-
tion is generally assessed relative to the glucose stimulus. Thus
in the absence of any known direct pharmacological effect of
voglibose on β-cell function, reduced insulin secretion in the
face of a small glucose stimulus is not surprising. Vildagliptin,
on the other hand, is known to increase β-cell function;
and this could be the reason for increased insulin secretion
observed in the vildagliptin group relative to that seen with
voglibosein response toa smallglucosestimulus in the present
study [26,27]. Furthermore, signiﬁcant increase in HOMA-β
in the vildagliptin group compared with that in the voglibose
group was observed in the present study, and HOMA-β at
endpoint in the vildagliptin group reached about 40% which is
considered as normal value in Japanese population.
The change in fasting lipid levels from baseline in both
treatment groups was not of clinical signiﬁcance. In previous
studies in a wide selection of populations including Chinese,
Asian and Non-Indian Asians, treatment with vildagliptin did
not lead to any major changes in the fasting lipid proﬁle [28].
In the vildagliptin group, the body weight increased by 0.2 kg,
which is not clinically signiﬁcant, whereas in the voglibose
group a decrease of 0.8 kg in bodyweight was noted, and it was
found that there was a statistical signiﬁcant difference between
the groups (p < 0.001). The statistical signiﬁcance achieved is
basicallybecauseofthebodyweightlossinthevoglibosegroup.
Vildagliptin was better tolerated compared with voglibose.
Noeventsofhypoglycaemiawerereportedduringthe12 weeks
of treatment with vildagliptin, whereas one hypoglycaemic
event in one subject was reported in the voglibose group. The
incidence of SAEs was 2.1% in the voglibose group, whereas
none was reported in the vildagliptin group (0%), and the
incidence of AEs (61.2% with vildagliptin vs. 71.4% with
voglibose) and suspected drug-related AEs were lower (25.0%
with vildagliptin vs. 40.6% with voglibose). There was a lower
prevalence of GI AEs on treatment with vildagliptin 50 mg
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bid (18.6%) compared with that with voglibose 0.2 mg tid
(32.8%). The α-glucosidase inhibitors are generally associated
with GI AEs, which could be a safety concern.
In this study, vildagliptin 50 mg bid was more effective in
reducing HbA1c and plasma glucose (FPG and 2-h PPG) with
enhancedβ-cellpreservationindicatedbyHOMA-β compared
with voglibose 0.2 mg tid. Furthermore, vildagliptin treatment
was associated with good tolerability, especially GI tolerability
without hypoglycaemia.Thus early treatment with vildagliptin
may be a better option for ﬁrst line of therapy to reduce the
hyperglycaemiathatcharacterizestype2diabetes;however,the
short duration of the study treatment should be taken into
consideration while interpreting the results.
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Volume 12 No. 8 August 2010 doi:10.1111/j.1463-1326.2010.01222.x 707original article DIABETES, OBESITY AND METABOLISM
General Hospital; T. Imai, Tsuchiura Kyodo General Hospital;
K. Ogino, Ogino Hospital; Y. Segawa, Segawa Hospital;
S. Mashiba, Mashiba Clinic; M. Kato, Kato Clinic; Y.
Aiso, Aiso Clinic; M. Sugawara, Sugawara Medical Clinic;
M. Noguchi, Shinagawa East One Medical Clinic; O. Miho,
Miho Clinic; T. Kabaya, Minamisenju Hospital; H. Onda,
Tokyo Clinical Research Organization for Medicine Clinic;
M. Fujita, Shinanozaka Clinic; I. Matsuba, Matsuba Clinic;
K. Iemitsu, Kounandai Iemitsu Clinic; M. Tokui, Tokui
Clinic; T. Iizuka, Asahi Medical Clinic; T. Takuma, Takuma
Saiwai Clinic; M. Nakagawa, Matsumoto Nakagawa Hospital;
T. Ohya, Ohya Medical Clinic; G. Watanabe, Watanabe Clinic;
N. Takahashi, Takahashi Family Clinic; H. Murase, Daiyukai
Clinic; H. Okamoto, Meitetsu Hospital; A. Kashiwagi, Shiga
UniversityofMedicalScience Hospital;S.Kanada,Heishin-kai
OCROM Clinic; S. Kajiyama, Medical Corporation Keisei-kai
KajiyamaClinic;S.Ohashi,ClinicKomatsu;T.Okuno,Nippon
Kokan Fukuyama Hospital; Y. Tajiri, Fukuoka City Medical
AssociationHospital;N.Inokuchi,InokuchiInternalMedicine
Clinic; N. Abe, Abe Diabetes Clinic; M. Hiraga, Nakamura
Hospital; S. Nakamura, Heiwadai hospital; T. Kuribayashi,
Koga General Hospital; T. Miyakawa, Tama Minami Clinic;
O. Tomonaga,TomonagaClinic;C.Kondo,MasukoMemorial
Hospital;N.Miyamoto,SainoClinic;M.Kaneshiro,Kaneshiro
Diabetes Clinic; T. Miyagishi, Miyagishi Hospital; S. Otabe,
Otabe Clinic; K. Shin, Shin Clinic.
708 Iwamoto et al. Volume 12 No. 8 August 2010